Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in addition to ADT in Chinese Participants With High-risk nmCRPC
NCT05171387Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Primary endpoint: Prostate-specific antigen response rate of >=50% decline. Started Nov 2021; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05171387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171387.